Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling

Area of Science:

• Pharmacology
• Infectious Diseases
• Nephrology

Background:

• Cytomegalovirus (CMV) infections are a significant concern in immunocompromised patients, including those with HIV and solid-organ transplants.
• Ganciclovir is a primary antiviral medication used to treat CMV infections.
• Understanding ganciclovir pharmacokinetics is crucial for optimizing treatment efficacy and minimizing toxicity.

Purpose of the Study:

• To investigate the pharmacokinetic variability of ganciclovir in diverse populations of CMV-infected patients.
• To identify key covariates influencing ganciclovir serum clearance.
• To compare ganciclovir clearance rates across different patient groups.

Main Methods:

• Utilized nonlinear mixed-effects modeling to analyze ganciclovir pharmacokinetic data.
• Assessed the impact of patient weight and estimated creatinine clearance on ganciclovir clearance.
• Compared ganciclovir clearance in CMV-infected patients with HIV and those who underwent solid-organ transplantation.

Main Results:

• Patient weight and estimated creatinine clearance were confirmed as significant covariates affecting ganciclovir clearance.
• HIV-infected patients with CMV retinitis exhibited 41% faster ganciclovir clearance compared to HIV-infected patients with CMV shedding only in urine.
• Solid-organ transplant recipients showed substantially lower ganciclovir serum clearance (one-fourth) than HIV-infected patients, even after adjusting for creatinine clearance.

Conclusions:

• Significant pharmacokinetic differences in ganciclovir clearance exist among different CMV-infected patient populations.
• These findings suggest potential need for population-specific ganciclovir dosing adjustments.
• Prospective validation is required to confirm these implications for clinical practice.